Hua Medicine Ltd. (HK:2552)
:2552
Want to see HK:2552 full AI Analyst Report?
2552 Stock Chart & Stats
HK$3.29
-HK$0.05(-3.62%)
At close: 4:00 PM EST
HK$3.29
-HK$0.05(-3.62%)
Day’s Range― - ―
52-Week RangeHK$1.87 - HK$4.95
Previous CloseN/A
Volume1.46M
Average Volume (3M)6.34M
Market Cap
HK$3.25B
Enterprise ValueHK$2.14B
Total Cash (Recent Filing)HK$1.09B
Total Debt (Recent Filing)HK$301.80M
Price to Earnings (P/E)2.5
Beta1.26
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding1,056,605,000
10 Day Avg. Volume6,422,209
30 Day Avg. Volume6,335,350
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.71
Price to Sales (P/S)5.69
P/FCF Ratio-45.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.16
Revenue Forecast (FY)HK$1.03B
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSustained revenue acceleration signals expanding product adoption and commercial traction in Hua's core diabetes franchise. Durable top-line growth supports scale for R&D and commercialization, improving the odds of reaching operating leverage over the medium term.
Improved Gross MarginA material gross margin improvement reflects stronger product economics or pricing power and lower COGS, which is a structural benefit. Higher margins create room for investment in sales and R&D while reducing the revenue needed to approach sustainable operating profitability.
Stronger Balance Sheet PositionLeverage at ~0.30 and restored positive equity reduce immediate refinancing risk versus 2024. Stable total debt and a rebuilt equity base provide financial flexibility to fund trials, commercial expansion or partnerships without acute solvency pressure over the next several quarters.
Bears Say
Persistent Operating LossesLarge negative operating and EBITDA margins show the core business remains unprofitable on an operational basis. That structural loss profile requires continued external funding or significant margin improvement to sustain operations and invest in commercialization over the medium term.
Weak Cash GenerationNegative OCF and FCF indicate cash burn despite reported net income, undermining internal funding capacity. Over 2–6 months this raises reliance on financing or equity resources for trials and commercial investment and increases execution risk if cash generation does not recover.
Earnings Quality & VolatilityNet income strength appears to be influenced by non-operating items while operating cash flow is negative, and equity has swung materially. This volatility complicates forecasting, reduces confidence in recurring earnings, and raises funding and governance concerns long-term.
Hua Medicine News
2552 FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was HK$1.87 and its highest was HK$4.95 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is HK$3.25B.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 106 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.085.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of -HK$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.634%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HK:2552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
2552 Company Deck
2552 Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
HUTCHMED (China)
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Options Prices
Currently, No data available
---